Literature DB >> 14670327

DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response.

Penelope A Morel1, Dewayne Falkner, Jeffrey Plowey, Adriana T Larregina, Louis D Falo.   

Abstract

DNA immunisation by intramuscular (IM) injection induces Th1 responses, whereas gene gun (GG) immunisation into the skin stimulates Th2 responses. Three ovalbumin (OVA) cDNA constructs, in which OVA is cytoplasmic (CYT), secreted (SECR), or transmembrane (TM), were compared in immunisation studies using intramuscular injection or biolistic bombardment of the skin. Gene gun immunisation with OVA-CYT or OVA-TM led to strong OVA-specific CTL responses, but not following OVA-SECR immunisation. In contrast, intramuscular immunisation with OVA-SECR or OVA-TM led to potent CTL while immunisation with OVA-CYT was ineffective. OVA-specific antibodies were detected following gene gun immunisation with all three constructs, whereas only the OVA-SECR construct induced antibody production following intramuscular immunisation. These results demonstrate the capacity to manipulate the nature of the immune response by altering the cellular localization of expressed proteins and the route of DNA immunisation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14670327     DOI: 10.1016/j.vaccine.2003.07.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 2.  Micro-scale devices for transdermal drug delivery.

Authors:  Anubhav Arora; Mark R Prausnitz; Samir Mitragotri
Journal:  Int J Pharm       Date:  2008-08-30       Impact factor: 5.875

3.  Designing the optimal vaccine: the importance of cytokines and dendritic cells.

Authors:  Penelope A Morel; Michael S Turner
Journal:  Open Vaccine J       Date:  2010

4.  Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice.

Authors:  Kevin S Goudy; Bo Wang; Roland Tisch
Journal:  Clin Immunol       Date:  2008-10       Impact factor: 3.969

5.  Development and use of SIV-based Integrase defective lentiviral vector for immunization.

Authors:  Zuleika Michelini; Donatella R M Negri; Silvia Baroncelli; Massimo Spada; Pasqualina Leone; Roberta Bona; Mary E Klotman; Andrea Cara
Journal:  Vaccine       Date:  2009-06-11       Impact factor: 3.641

Review 6.  Exosomes: Emerging implementation of nanotechnology for detecting and managing novel corona virus- SARS-CoV-2.

Authors:  Akhilesh Dubey; Cynthia Lizzie Lobo; Ravi Gs; Amitha Shetty; Srinivas Hebbar; Sally A El-Zahaby
Journal:  Asian J Pharm Sci       Date:  2021-10-03       Impact factor: 6.598

Review 7.  Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic.

Authors:  Wang Ziqi; Cui Kai; Ulrich Costabel; Zhang Xiaoju
Journal:  Exploration (Beijing)       Date:  2022-07-21

8.  Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.

Authors:  Z Zhang; C Kuscu; S Ghazizadeh
Journal:  Gene Ther       Date:  2009-05-14       Impact factor: 5.250

9.  Skin Immunization Obviates Alcohol-Related Immune Dysfunction.

Authors:  Rhonda M Brand; John Mark Stottlemyer; Rachel A Cline; Cara Donahue; Jaideep Behari; Louis D Falo
Journal:  Biomolecules       Date:  2015-11-06

10.  A Simple and Efficient Genetic Immunization Protocol for the Production of Highly Specific Polyclonal and Monoclonal Antibodies against the Native Form of Mammalian Proteins.

Authors:  Julie Pelletier; Hervé Agonsanou; Fabiana Manica; Elise G Lavoie; Mabrouka Salem; Patrick Luyindula; Romuald Brice Babou Kammoe; Jean Sévigny
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.